Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
PharmaIN
WA - Bothell
CAPTOPRIL (captopril) by PharmaIN is angiotensin-converting enzyme inhibitors [moa]. Approved for hypertension, diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus, retinopathy and 8 more indications. First approved in 1996.
Drug data last refreshed 2h ago
Angiotensin-converting Enzyme Inhibitors
Angiotensin Converting Enzyme Inhibitor
Worked on CAPTOPRIL at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study on the Application of Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Aldosterone and Renin Activity in the Diagnosis of Primary Aldosteronism by Captopril Test
Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions
Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo